Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Roche wins Japan approval for personalised cancer drug Rozlytrek

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/18/2019 | 03:29am EDT
FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

ZURICH (Reuters) - Swiss drugmaker Roche's push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

Japan is the first country to give its blessing to Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types including breast, colorectal, neuroendocrine, lung and pancreatic cancers.

Rozlytrek aims to treat people with a rare genetic anomaly, called NTRK fusions, that drive growth in a range of tumours found throughout the body. This approach, where prospective patients must be identified via a biomarker test, is a departure from an era when doctors treated patients based on where the tumour occurred in the body.

While positive news for Roche, the Basel-based company has been beaten to the regulatory finish line in this emerging area: German drugmaker Bayer's Vitrakvi has already won U.S. backing for solid tumours that test positive for NTRK genes. Roche has yet to get U.S. and European approvals.

"Today's approval of Rozlytrek represents a new chapter in personalised healthcare, applying advanced diagnostics to deliver precision medicines," said Sandra Horning, Roche’s chief medical officer, adding she hopes for approval elsewhere "as soon as possible".

On their own, NTRK fusions are so rare that doctors are not likely to run dedicated tests for each. But since they occur in a multitude of tumours, Roche sees potentially broad application for Rozlytrek, in conjunction with companion diagnostic tests from its Foundation Medicine unit.

Roche is also testing Rozlytrek in cancers with additional genetic anomalies.

(Reporting by John Miller; Editing by Michelle Martin)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.13% 59.61 Delayed Quote.-1.67%
ROCHE HOLDING LTD. 0.15% 265.05 Delayed Quote.8.73%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
06:52aBAYER COULD BENEFIT FROM HOME ADVANT : experts
RE
04:27aBAYER : Drug Iberogast Under Investigation -Handelsblatt
DJ
07/19BAYER : Syngenta profits hit by U.S./China trade wars, bad weather
RE
07/19BAYER : welcomes judge's call for reduced damages in $2 billion glyphosate case
RE
07/19BAYER : Correction to Bayer Verdict Article
DJ
07/19Does renewables pioneer Germany risk running out of power?
RE
07/19BAYER : Judge Cuts Third Bayer Roundup Verdict in Tentative Ruling
DJ
07/17BAYER : Leads Investment in U.S. Oncology Startup
DJ
07/17Activist hedge fund Elliott takes stake in UK's Saga
RE
07/16GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
More news
Financials (EUR)
Sales 2019 46 326 M
EBIT 2019 8 877 M
Net income 2019 3 589 M
Debt 2019 37 542 M
Yield 2019 4,80%
P/E ratio 2019 17,0x
P/E ratio 2020 12,4x
EV / Sales2019 2,01x
EV / Sales2020 1,90x
Capitalization 55 496 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,90  €
Last Close Price 59,51  €
Spread / Highest target 107%
Spread / Average Target 30,9%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-1.67%62 271
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273